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Abstract
  Childhood asthma is a common complex condition whoseBackground.
aetiology is thought to involve gene-environment interactions in early life
occurring at the airway epithelium, associated with immune dysmaturation.  It is
not clear if abnormal airway epithelium cell (AEC) and cellular immune system
functions associated with asthma are primary or secondary.  To explore this,
we will (i) recruit a birth cohort and observe the evolution of respiratory
symptoms; (ii) recruit children with and without asthma symptoms; and (iii) use
existing data from children in established STELAR birth cohorts.    Novel
pathways identified in the birth cohort will be sought in the children with
established disease.  Our over-arching hypothesis is that epithelium function is
abnormal at birth in babies who subsequently develop asthma and progression
is driven by abnormal interactions between the epithelium, genetic factors, the
developing immune system, and the microbiome in the first years of life.
  One thousand babies will be recruited and nasal AEC collected atMethods.
5-10 days after birth for culture.  Transcriptomes in AEC and blood leukocytes
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 Discuss this article
 (0)Comments
5-10 days after birth for culture.  Transcriptomes in AEC and blood leukocytes
and the upper airway microbiome will be determined in babies and again at one
and three years of age. In a subset of 100 individuals, AEC transcriptomes and
microbiomes will also be assessed at three and six months.  Individuals will be
assigned a wheeze category at age three years.  In a cross sectional study, 300
asthmatic and healthy children aged 1 to 16 years will have nasal and bronchial
AEC collected for culture and transcriptome analysis, leukocyte transcriptome
analysis, and upper and lower airway microbiomes ascertained.  Genetic
variants associated with asthma symptoms will be confirmed in the STELAR
cohorts. 
  This study is the first to comprehensively study the temporalConclusions.
relationship between aberrant AEC and immune cell function and asthma
symptoms in the context of early gene-microbiome interactions.
Keywords
Asthma, Child, Epithelial cell, Genetics, Infant, Longitudinal studies,
Lymphocyte, Microbiome, Ribonucleic acid
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Introduction
Asthma is the most common non-communicable disease of 
childhood and affects 1 million children in the UK1. A child is 
admitted to hospital for a severe asthma attack every 20 minutes 
in the UK1, with many more seeking unscheduled healthcare 
assistance with less severe attacks. Regular apparently “minor” 
asthma symptoms can affect the child’s sleep, exercise, school 
attendance and mental wellbeing. The NHS budget for asthma 
treatment is approximately £1 billion1 with approximately 25% 
of this being spent on children, and one in twenty school-aged 
children are prescribed asthma preventer treatment. Childhood 
asthma is a life-long burden to the individual since symptoms 
often persist into adulthood. Asthma is associated with early 
poor lung function, which persists into adult life, leading to 
increased risk of chronic obstructive pulmonary disease2,3, which 
is the fourth most common cause of death in the UK. 
There is no prospect of a cure for asthma at the time of writing, 
but the potential for prevention of asthma by modification of the 
antenatal and early post-natal environment has been demonstrated. 
In the Isle of Wight Allergy Prevention Study, a randomised 
trial where the intervention delivered reduced maternal and infant 
inhaled and ingested allergen exposure during early develop-
ment, was associated with a 75% reduction in risk for asthma 
at 18 years of age4. In the Canadian Asthma Prevention Study, a 
similar multi-faceted environmental intervention lead to a 
50% reduction in asthma to ten years of age5. What is not clear 
is the mechanism underlying these effective interventions.
For many years, asthma was considered to be a respiratory 
manifestation of allergy secondary to a mechanism involving 
aberrant cellular immune responses to common environmental 
antigens6. This paradigm has now been reconsidered7 and the 
central role of airway epithelial cells (AEC) in the development 
of asthma has become a focus of research8. The AEC is the site 
of initial encounters between inhaled particles and the respiratory 
system, and is known to be an important component of the 
innate system and adaptive immunity modulation, with many 
genes associated with asthma identified from genome-wide asso-
ciation studies that are expressed in the airway epithelium9. 
Two systematic reviews have described many differences 
between the characteristics of AEC from children with and 
without asthma10,11. One proof-of-concept study described 
differences in neonatal nasal AEC function for individuals who 
went on to have asthma symptoms at age four years compared 
to those who did not12. This study12 also observed that not all 
individuals with abnormal neonatal AEC function went on to 
have asthma symptoms, suggesting that asthma requires both 
abnormal neonatal AEC function and at least one other factor. 
The microbiome of the neonatal airway, i.e., the populations of 
commensal bacteria in the airway, is also thought to be impor-
tant to the development of asthma and may be important to the 
progression from abnormal AEC function to childhood asthma. 
Nasopharyngeal colonisation within the first 28 days with 
M catarrhalis, H influenzae or S pneumoniae is associated with 
a greater subsequent risk of asthma13, and an abnormal mucosal 
immune response14. Asthma is a complex condition where 
multiple factors (which could include AEC and lymphocyte 
function, the microbiome and familial traits) are accepted as 
being important to the underlying mechanism.
The Breathing Together consortium has come together to con-
sider how AEC function is related to childhood asthma and 
how this relationship is influenced by lymphocyte function, the 
microbiome, and genetic variants in early life which ultimately 
results in abnormal AEC responses to infectious and non- 
infectious environmental exposures. Our over-arching hypothesis 
is that epithelial function is abnormal at birth in babies who 
subsequently develop asthma and progression is driven by 
abnormal interactions between the epithelium, genetic factors, 
the developing immune system, and microbial community in the 
first years of life. 
Our programme of research will also consider how other factors 
linked to asthma causation15 may be involved in the development 
of asthma, including exposure to second hand cigarette smoke 
and respiratory viruses. The purpose of this paper is to describe 
our key research questions, aims and methodology for our study, 
called Breathing Together (http://breathingtogether.co.uk/).
Key research questions: 
1. How does pulmonary epithelial function evolve from birth 
to six years in children who develop asthma, and how does the 
epithelium interact with the evolving immune system and airway 
microbiome?
2. What are the mechanisms whereby pathogens and aeroaller-
gens modulate epithelial-immune interactions, skewing airway 
responses towards asthma rather than resolution?
3. Can these pathways be used to identify biomarkers of 
asthma development, enabling future preventive strategies?
Our aims are: 
1.  To examine evolution of epithelial cell function during the first 
years of life, and determine the causal relationships with the 
maturing immune system and airway microbiome.
2.  To investigate the molecular mechanisms whereby epithelial-
immune-microbial-gene interactions are skewed towards asthma 
rather than resolution.
3.  To identify biomarkers for asthma development, enabling future 
disease modifying interventions.
Objectives 
1.  Recruit newborn babies with detailed antenatal history, and 
obtain nasal epithelial cells, blood and other samples at 
five to ten days of age, and follow them longitudinally for 
three years with serial sampling, retrospectively phenotyp-
ing them depending on whether or not they develop recurrent 
wheeze (see Methods section 2.1)
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2.  To understand the normal and abnormal developmental 
interactions between the airway epithelium, the host immune 
system and the airway microbiome, by comparing the evolving 
changes in immune and epithelial function in recurrent 
wheezers from a birth cohort (see Methods section 2.1) with the 
pathobiology of established mild and severe wheezers (see 
Methods sections 2.2, 2.3 and 2.4). 
3.  Utilize longitudinal data on childhood wheezing and genetics 
generated from established large UK birth cohorts (STE-
LAR) to determine if the genetic signals in the pathways and 
molecules identified in objective two correspond to the different 
epidemiological/genetic wheeze phenotypes identified in 
STELAR. 
Methods
1 Programme design
The programme design includes four participant groups and five 
work streams. Figure 1 summarises how the participant groups 
are integrated. Recruitment to the participant groups began in 
December 2016 and will continue until Feb 2020. All partici-
pants will have nasal AEC collected for culture and transcrip-
tomics, blood or saliva samples collected for DNA analysis, 
whole blood for RNA transcriptomics, urine sample for coti-
nine levels and upper airway samples collected for microbiome 
(see Table 1). Accessing bronchial AEC in healthy neonates is not 
feasible and nasal AEC will be used as surrogates for bronchial 
AEC in the neonates we will recruit. Nasal AEC have been shown 
to be valid surrogates for bronchial cells in five studies involving 
a total of 124 infants and children16–20. Bronchial AEC, the gold 
standard for studying AEC function, will be collected from 
young children (aged one to ≤ five years) and older children with 
and without wheeze, when they are under general anaesthetic for a 
clinically-indicated operation. There are four participant groups:
•     Group one (see Figure 2, Methods section 2.1) will consist 
of a birth cohort of 1000 term singleton neonates where 
≥50% have a first-degree family history and from whom 
nasal AEC will be collected at five to ten days of age and 
at one and three years thereafter. In total, 100 individuals 
within participant group one will also have upper airway 
samples collected for microbiome assessment at three and 
six months to describe normal colonisation of the upper 
airways. The remaining 900 individuals in participant group 
one will form an observational cohort where blood, nasal 
AEC and nasal secretions will be collected on a wheezy 
episode after six months of age, with blood being 
collected in convalescence after six to eight weeks. 
•     Group two (see Methods section 2.2) will include 200 
young children (≤five years) with mild to moderate wheez-
ing, and healthy children with no respiratory symptoms; 
nasal and bronchial AEC will be collected from participants 
when they undergo general anaesthetic for a clinically- 
indicated operation (Table 1). 
•     Group three (see Methods section 2.3) will consist of 
50 children up to six years of age with severe wheeze 
undergoing a clinically indicated bronchoscopy. Nasal and 
bronchial AEC, bronchoalveolar lavage fluid and bronchial 
biopsy tissue will be collected from participants (Table 1). 
Spirometry and exhaled nitric oxide will be measured using 
standard methodologies21,22 in participants where possible. 
•     Group four (see Methods section 2.4) consists of 50 older 
children with severe asthma undergoing a clinically indicated 
Figure 1. A schematic diagram showing how the participant groups are interlinked.
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Table 1. A summary of which samples are collected in each of the four participant groups (PG). mRNA= messenger ribonucleic acid, 
AEC=airway epithelial cells. *mRNA expression in AEC (but not AEC culture) and lymphocytes also collected at 12 months and three years. 
†swabs also collected at 12 months and three years of age for all participants and in a subgroup of 100 individuals at three and six months.
Nasal AEC 
for culture 
and mRNA 
expression
Nasal and 
throat 
swabs for 
microbiome
Urine 
for 
cotinine
Blood for 
lymphocyte 
mRNA 
expression
Blood or 
saliva for 
DNA
Bronchial 
AEC for 
culture 
and mRNA 
expression
Bronchial 
fluid for 
microbiome
Broncho- 
alveolar 
fluid
Bronchial 
biopsy
PG one (birth cohort) √* √† √ √* √
PG two (mild 
preschool wheeze 
and control)
√ √ √ √ √ √ √
PG three (severe 
preschool wheeze) √ √ √ √ √ √ √ √ √
PG four (severe 
asthma in older 
children)
√ √ √ √ √ √ √ √ √
Figure 2. A flow diagram describing the participant’s journey for individuals in participant group one. 
bronchoscopy. They will be accessed in the same way as 
participant group three.
Lower airway microbiome will be determined in all individuals 
except those in participant group one.
Ethics approval has been obtained for all aspects of the study 
(reference numbers 16/LO/1518 [London City and East] and 
17/LO/0013 [London-Riverside Research Ethics Committee]). 
Written informed consent will be obtained from parents and (where 
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appropriate) assent obtained from participants. Material transfer 
agreements are in place.
2 Participant groups
2.1 Participant group one (birth cohort) 
2.1.1 Recruitment and eligibility. This will take place either 
in the antenatal clinic or on the postnatal ward in five centres 
(Aberdeen, Edinburgh, London Imperial College, London Queen 
Mary University Hospital and Isle of Wight). Inclusion criteria 
will be being born at term (i.e. between 37 and 42 weeks) and 
having a parent who is able to give written informed consent. 
There will be no initial active selection for offspring at increased 
risk for asthma since our earlier work indicates that the nature 
of this study will likely lead to a participant group which is 
enriched with individuals with a family history of asthma. 
Exclusion criteria include: twins or other multiple pregnan-
cies; maternal group B streptococcus on high vaginal swab or 
urine culture in the present pregnancy (brushing a neonatal nose 
colonised with this bacterium may lead to invasive infec-
tion); need for CPAP or ventilatory support before samples are 
collected; major concurrent health problems, e.g. congenital 
heart disease, cystic fibrosis; infants who will not be available to 
attend acutely if they develop wheeze; infants who are likely to 
move away from the study centre before three years of age.
2.1.2 Questionnaires. The parents will complete a baseline 
questionnaire to collect data about family history, environment, 
pregnancy, delivery and early neonatal period (Supplementary 
File 1). These data will be collected in the first week of life. 
Common questions will be used across all participant groups. 
In addition to baseline questions, a very short online question-
naire will be completed each month by parents until their child is 
36 months of age (Supplementary File 2). To give insight into 
the natural history of the establishment of airway microbiome 
for individuals with asthma and without asthma, a subgroup 
(n=100) will have additional throat and nasal swabs for micro-
biome analysis at three and six months; a short questionnaire 
will be completed at the three and six month assessments (Sup-
plementary File 3). Commercially available software (Qualtrics) 
will email parents with a link to that month’s questionnaire. Par-
ents will have access to a video of wheeze to provide a standard 
definition of parental reported wheeze. Where families do not 
have internet access, researchers will call or text the family on 
a monthly basis. All participants will be assessed with the same 
questionnaire at ages one and three years (Supplementary File 4). 
This will capture any episodes of wheeze, atopic diseases, any 
treatment, current environment, nutrition and environment. 
Questions will be from the International Study of Asthma 
and Allergy in Children respiratory and eczema modules23 
(Supplementary File 4).
2.1.3 Acute wheeze assessment. For participants who are not part 
of the subgroup (n=100) having additional serial upper airway 
swabs for microbiome analysis, parents will be invited to contact 
the team on one (and ideally the first) occasion that their child 
has an episode of wheeze after 6 months of age (wheeze before this 
age is likely to be due to infection). A clinical assessment will take 
place within five days from onset of symptoms. Previously 
validated questionnaires (Jackson cold score24 and Ducharme 
pre-school asthma exacerbation questionnaire25) will capture 
details of symptoms (Supplementary File 5). These participants 
will be reassessed six to eight weeks later for a convalescent 
visit. A convalescent questionnaire will be completed, cover-
ing symptoms associated with the acute illness, their current 
healthcare utilisations and any treatment (Supplementary File 6). 
Clinical assessments. Participants will be examined by a trained 
nurse or doctor at the baseline, one year, and three years. The 
chest will also be assessed for the presence of wheeze at the 
symptomatic and convalescent assessments and severity of 
eczema will be assessed using a standard methodology (SCO-
RAD)26 (Supplementary File 7). Skin prick testing will be under-
taken at three years of age with nine common allergens (house 
dust mite [HDM], grass pollen, tree pollen, cat, dog, alternaria, 
cows’ milk and egg, eanut and any other clinically relevant 
allergen; ALK-Abello, Denmark) using the standard method-
ology27. A mean wheal diameter of ≥3mm will be regarded as 
positive in the presence of appropriate control responses.
2.2 Participant group two (mild preschool wheeze and controls) 
2.2.1 Recruitment and eligibility. We will recruit young children 
(aged between twelve months and ≤five years) with a history of 
mild to moderate wheezing, and those without previous wheez-
ing. Such children do not ordinarily have samples taken from the 
lower airways in routine practice and to do this purely for 
research purposes cannot be justified as it requires the use of 
anaesthesia. We therefore will use blind bronchial brushing28,29 
to collect samples from children who are already undergoing 
anaesthesia for an elective surgical procedure. Our team is expe-
rienced in this methodology18,30. In addition to being scheduled 
for elective general anaesthetic, inclusion criteria include age 
one to ≤five years at the time of sampling and being free from 
recent respiratory tract infection. Exclusion criteria include: 
born preterm (i.e. <37 gestation); recent respiratory tract illness 
(i.e. symptoms resolved for < two weeks); other chronic respiratory 
illnesses (e.g. Cystic Fibrosis); a history of previous pituitary or 
ethmoid surgery.
We will recruit 50 children in each of the following four 
categories:
1.    Wheeze and atopy. Recurrent wheezing (more than two 
episodes of confirmed wheezing with at least one episode in the 
last six months) and other clinical atopy (e.g., eczema and/or 
allergic rhinitis).
2.    Wheeze and no atopy. Recurrent wheezing (more than two 
episodes of confirmed* wheezing with at least one episode in the 
last six months) and no obvious wheezing triggered by 
aeroallergens and no clinical evidence of other atopy.
3.    No wheeze and atopy. No history of wheezing but with at least 
one clinically apparent atopic disorder (e.g. eczema and/or 
allergic rhinitis)
4.    No wheeze or atopy. No history of wheezing and with no 
clinical evidence of other atopic disorder
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Wheezing will be confirmed by parents after viewing an 
audio-video clip of true wheezing.
2.2.2 Questionnaires. The same questionnaires used in group 
one will be used here (Supplementary File 1 and Supplementary 
File 4). Respiratory signs and symptoms and including details26 
of eczema (Supplementary File 7) will be documented in 
participant groups two, three and four.
2.3 Participant group three (severe pre-school wheeze) 
2.3.1 Eligibility criteria. Inclusion criteria for this group include: 
age twelve months to ≤six years; a history of recurrent episodes 
of wheeze and difficulty in breathing; due to undergo a clinically 
indicated bronchoscopy. Exclusion criteria are the same as 
participant group two (see Methods section 2.1.1).
2.3.2 Questionnaire. The same questionnaire will be used for all 
participant groups (Supplementary File 1 and Supplementary 
File 4).
2.4 Participant group four (severe asthma in older children) 
2.4.1 Eligibility criteria. Inclusion criteria for this group are also 
described elsewhere31: age six to 16 years; diagnosis of severe 
asthma made by specialist paediatrician (see Supplementary 
File 8); documented wheeze by healthcare professional; evidence 
of one or more of airway hyper-responsiveness confirmed by 
direct or indirect challenge, bronchodilator reversibility (≥12%) 
or peak expiratory flow variability of ≥10%. Exclusion crite-
ria include those for participant group two (see section 2.1.1) 
plus the following: significant alternative diagnoses that may 
mimic or complicate asthma, in particular dysfunctional breath-
ing, panic attacks, and overt psychosocial problems (if these 
are thought to be the major problem rather than in addition to 
asthma); Poor adherence to therapy demonstrated following a 
period of electronic monitoring
2.4.2 Questionnaire. The same questionnaire will be used for all 
participant groups (Supplementary File 1 and Supplementary File 4).
3 Collection of samples
Table 1 identifies which samples are collected in each participant 
group.
3.1 Nasal brushings for AEC. Each nostril will be brushed once      
with a Dent-o-Care interdental brush 620 (2.7mm brush)32. One 
brush will be used for airway epithelial cell culture and will be 
inserted into a sterile 15 ml polypropylene collection tube 
containing 5ml of DMEM. DMEM medium containing peni-
cillin and streptomycin antibiotics will be added to the 
polypropylene tube. Samples will be place in a sealed sterile 
plastic bag and transported, within 72 hours, to the tissue cul-
ture laboratory. The second brush (for airway epithelial gene 
analysis) will be placed into an Eppendorf containing RLT buffer 
(Qiagen) with 2Mercaptoethanol (ME) added and frozen at -80°C 
prior to transportation to the laboratory for RNA extraction and 
transcriptomics analysis.
3.2 Bronchial brushings for AEC. For participant group two, 
blind brushings will be obtained by passing a sheathed bronchial 
cytology brush (10-mm disposable cytology brush, BC 
202D-2010, Olympus, Southend-on-Sea, Essex, UK) through 
the endotracheal tube until resistance is felt28,29. Once resist-
ance is met, the sheath is withdrawn and the brush gently moved 
with up/down and rotational action before the sheath is returned 
to its initial position and the brush removed. For participant 
group three and four bronchial AEC will be obtained under 
direct vision during bronchoscopy. Briefly, a sheathed bronchial 
cytology brush is inserted though the working channel of the 
bronchoscope, the brush is advanced through the protective 
sheath and gentle brush sampling obtained using an up/down 
and rotational action, the sheath is replaced and the brush 
removed. The brush head is then cut off and used for cell culture 
as described above. This process is repeated to collect a sample 
for mRNA analysis as described above. 
3.3 Blood sampling. For all participant group members, 50 µl 
whole blood will be collected by Minivette® into specifically 
prepared tubes with PAXgene Blood RNA reagent. The sample 
will be stored at –20°C, within 60 mins of collection and will be 
used for whole genome gene expression arrays in workstream 
four (see Methods section 4). For participant groups two, three and 
four, blood will be collected for measurement of (i) total serum 
IgE, (ii) specific IgE to nine common allergens (HDM, grass pol-
len, tree pollen, cat, dog, alternaria, cows’ milk and egg, peanut 
and any other clinically relevant allergen), specific IgE >0.35 is 
considered positive, and (iii) immune and inflammatory cells 
in the blood using flow cytometry and genotype.
3.4 Airway samples for microbiome analysis. Separate swabs 
(ESwab, Becton Dickinson, Wokingham, UK) will be taken 
from the nose and oropharynx. For individuals in participant 
groups two, three and four a bronchoscopy cytology brush 
(10-mm disposable cytology brush, BC 202D-2010, Olympus, 
Southend-on-Sea, Essex, UK) will be passed into the airways 
until resistance is felt and then removed, the brush will be cut 
off and placed in an empty container (Falcon 15ml, Fisher 
Scientific, Loughborough, UK). The swabs will initially be stored 
at room temperature until transported back to the local labora-
tory at the site of collection, where they will be stored at -80°C 
until transported in batches on dry ice to the laboratory in Monash 
University for DNA extraction and analysis of the bacterial 
microbiome by 16S rRNA PCR sequencing. Control containers 
will also be collected for one in twenty individuals. BAL 
samples will also be used for assessment of the microbiome. 
The virome may also be tested using samples collected for 
microbiome studies and from whole blood RNA.
3.5 Broncho-alveolar lavage (BAL). For participant group two, 
after intubation the “blind” technique33 will be used and a suc-
tion catheter will be passed through the endotracheal tube until it 
meets resistance, then 1 ml/kg (to a maximum of 20 ml) of nor-
mal saline will be instilled via syringe into the catheter, and the 
fluid will be aspirated back with suction applied. For participants 
in participant group three and four, BAL will be collected 
using the bronchoscope34; here three aliquots of 1 ml/kg (to a 
maximum of 40 ml/aliquot) is passed into the airways after 
the bronchoscope is wedged and the fluid removed by suction. 
BAL will be spun, and supernatants stored at -80°C for future 
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analysis of inflammatory mediators. Counts of inflammatory 
cells, including neutrophils, eosinophils and lymphomononuclear 
cells will be performed on cell cytospins. Cells will be further 
characterised by flow cytometry at selected study centres and if 
sufficient cell numbers are obtained. 
3.6 Endobronchial biopsies. We have shown biopsies can be 
taken safely for research and without adding significant time to 
the procedure35. Up to four biopsies will be collected from the 
3rd or 4th generation sub-segmental bronchi. Biopsies will be 
fixed in formal saline for up to 24 hours and processed to 
paraffin blocks. Sections will be cut and stained with haematoxy-
lin and eosin to assess overall biopsy quality and morphology. 
Those containing recognisable epithelium, reticular basement 
membrane, and associated submucosa will be analysed further for 
airway inflammation and remodelling.
3.7 Urine for cotinine. Urine will be collected using a bag, and 
cotinine concentration determined by standard enzyme linked 
immune assay to objectively measure tobacco smoke exposure in 
the previous 24–36 hours.
3.8 Nasopharyngeal aspirate for virology from acute assessment 
in participant group one. Samples will be collected (UTM-RT 
swabs, COPAN, Murrieta, CA) and stored centrally in the 
Edinburgh laboratory and analysed by (RT)-PCR.
3.9 Data collection and sample tracking. A bespoke database 
and electronic case report form (CRF) has been created using 
InForm® software. This database provides a single portal which 
captures the responses to all the questionnaires and which allows 
samples to be identified and tracked. Figure 3 gives an overview 
of data management within the project. Usual quality control 
checks are in place, e.g. gender options either male or female, 
birth weight between 1500 g and 4500 g. Samples from each 
individual are barcoded and the bar code details linked to the 
participant’s CRF, and this allows participant details to be linked 
to samples wherever the samples are analysed.
4 Workstreams
There will be five workstreams. The first is the recruit-
ment of participants and collection of samples. The 
following four workstreams will include a series of experiments 
that will be conducted using samples collected from participants:
•      Workstream 2. Airway epithelial cells. Neonatal cells will 
be cultured at air liquid interface to achieve a differenti-
ated epithelial cell layer and, as previously12, responses 
to common environmental exposures will be compared 
between those who have asthma symptoms and those 
who have no asthma symptoms by three years of age. 
RNA will also be extracted from cells and a particu-
lar focus will be genes involved in tissue proliferation, 
repair and remodelling. Differences in responses to 
environmental exposures and in RNA expression will 
also be described in children with and without asthma in 
groups two, three and four.
Figure 3. Overview of data management within the project. †recruiting sites for groups 2–4 include Belfast, Southampton, Imperial College, 
Queen Mary’s and Aberdeen.
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•      Workstream 3. Microbiome. The evolving microbi-
ome characteristics from shortly after birth through to 
infancy will be described in the 100 individuals where 
repeated microbiome sampling takes place. Microbiome 
characteristics shortly after birth and at one and three 
years will be compared between group one partici-
pants who have asthma symptoms and who do not have 
asthma symptoms at three years of age. In a cross- 
sectional manner, microbiome characteristics will be 
described in children with and without asthma in groups 
two, three and four.
•      Workstream 4. Immune system. Whole genome gene 
expression array will be used to describe RNA expres-
sion in lymphocytes and how these change over time and 
in the context of evolving asthma symptoms by age three 
years in group one participants. Differences in RNA 
expression will also be sought between children with and 
without asthma in groups two, three and four.
•      Workstream 5. Genetics. Candidate genes which are 
known to be involved in tissue proliferation, repair and 
remodelling will be studied among participants in groups 
one, two, three and four. Additionally, genetic variants 
which are found to be of potential relevance to asthma 
within the STELAR cohorts will be described in the 
Breathing Together groups.
Many experiments will involve collaboration between work-
streams, for example immune system and genetics. State of the 
art technology, apparatus and analysis will be used in the experi-
ments. In anticipation of their being a limit to the availability 
of samples, we will have a hierarchy of questions to ensure that 
the key research questions are addressed whilst also making 
best use of the samples available to test hypotheses that arise 
during the course of our experiments.
5 Study results dissemination
Study results will be presented at international conferences and 
published in peer-reviewed journals. Research data will be made 
available once all data items are cleaned and indexed. We will 
publish data dictionaries and study metadata (without links to 
the source data) on the project website for future data sharing on 
request to the Ethics Committee.
Summary
The Breathing Together study brings together a multidiscipli-
nary team whose collaboration will yield answers to questions 
that are crucial to understanding asthma inception. The key 
outputs of Breathing Together will be to determine (i) whether 
neonatal AEC function (including response to virus and allergen) 
is “normal” before the onset of asthma symptoms, (ii) the relation-
ship between the maturing upper airway microbiome and immune 
system in early infancy and subsequent wheeze, how these are 
related to changes in AEC RNA pathways, and (iii) how 
genetic factors modify relationships between AEC and wheeze 
outcome. 
Recruitment began in December 2016 and Breathing Together 
teams have been established in Aberdeen, Belfast, Bristol, 
Edinburgh, Isle of Wight, London (Imperial College and Queen 
Mary University of London, QMUL), Manchester, Melbourne and 
Southampton. Samples are being collected and moved between 
centres for analysis, for example all leukocyte analysis will be 
undertaken in Edinburgh, Microbiome and AEC RNA analysis 
will be done in Melbourne, and urinary cotinine in QMUL. The 
AEC cultureexperiments will take place in three laboratories 
(Belfast and both London sites) and transport from Aberdeen, 
Edinburgh and Southampton has been piloted and proven 
effective, with cells being cultured and frozen for later analysis. 
Very clear standard operating procedures are in place between 
the three AEC laboratories, staff visit other laboratories and 
samples from the same individuals will be analysed in all three 
laboratories. 
Obtaining AEC samples from neonates presents a number of 
practical challenges, and even when these are overcome a small 
amount of cells are sometimes available which permits only a 
restricted number of experiments. Our primary AEC exposures 
will be HDM and respiratory syncytial virus to which cultures 
from all individuals will be exposed. We will retain AEC from all 
individuals in anticipation of the birth cohort being followed 
up beyond three years and novel methodologies and research 
questions arising in future. 
An important part of Breathing Together is its public engage-
ment. This is being delivered in collaboration with Okido 
(http://www.okido.co.uk/), a children’s science magazine which 
also features in a television programme (Messy goes to Okido). 
Okido aim to engage children aged three to five years in science 
and learning; the additional funding for this is the biggest Public 
Engagement grant awarded by The Wellcome Trust. 
In short, the Breathing Together team are taking a multidiscipli-
nary approach to deliver cutting edge research in partnership 
with infants, young children and their parents with an ultimate 
goal of bringing forward the day when asthma prevention is part 
of routine antenatal and perinatal practice.
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In this article the Authors describe the protocol for the Breathing Together study on the relationships
between abnormal airways epithelium cells, immune cell function and asthma symptoms in the context of
early gene-microbiome interactions.
The study is precisely and comprehensively described also with the help of diagrams. The rationale for
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Introduction:
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study.
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Participants for groups 3 and 4 will be recruited from the two London centres and
Southampton. 
We can confirm that children found to have a congenital airway narrowing at
bronchoscopy will not be categorised as wheezers or asthmatics.
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